| Li Zheng,Min Zhao,Xiangyang Hu,Jin Huang,Ling Ang,Hongguang Hu,Qiang Zou,Jin Wang,Mingqiang Liu,Yang Zhao. Clinical significance of HBME-1, Galectin-3, and CK19 expression and the status of BRAF mutation in papillary thyroid carcinoma. Oncol Transl Med, 2016, 2: 174-178. |
| Clinical significance of HBME-1, Galectin-3, and CK19 expression and the status of BRAF mutation in papillary thyroid carcinoma |
| Received:February 13, 2016 Revised:July 23, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:papillary thyroid carcinoma (PTC); human bone marrow endothelial cell markers (HBME-1); Galectin-3; cytokeratin19 (CK19); v-raf murine sarcoma viral oncogene homolog B1 (BRAF) |
| Author Name | Affiliation | E-mail | | Li Zheng | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Min Zhao | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | Zhao.Min.hi@163.com | | Xiangyang Hu | Department of Pathology, Anhui Medical University, Hefei 230032, China | zhengli352@163.com | | Jin Huang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Ling Ang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Hongguang Hu | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Qiang Zou | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Jin Wang | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Mingqiang Liu | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com | | Yang Zhao | Department of Pathology, The Second People’s Hospital of Hefei, Hefei 230011, China | zhengli352@163.com |
|
| Hits: 7102 |
| Download times: 7924 |
| Abstract: |
| Objective: The aim of this study was to explore the clinical significance of the expression of proteins
human bone marrow endothelial cell markers (HBME-1), Galectin-3, and cytokeratin19 (CK19), as well
as the status of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation in papillary thyroid
carcinoma (PTC).
Methods: Immunohistochemical staining was performed in 82 specimens each of PTC and papillary benign
lesions to detect the expression of HBME-1, Galectin-3, and CK19. Polymerase chain reaction (PCR)
and gene sequencing were performed on 60 specimens each of PTC and papillary benign lesions to detect
the status of BRAF mutation.
Results: The positive expression ratios of HBME-1, Galectin-3, and CK19 in PTC were 98.8%, 97.6%
and 100% respectively, which were significantly higher than the expressions in papillary benign lesions
(P < 0.05). No significant relationship was observed between the expression of these makers and the
clinicopathological features of PTC. The sensitivity of co-expression of HBME-1 and CK19 or HBME-1 and
Galectin-3 as diagnostic criteria of PTC was 99.9%, with a specificity of 95.4%. BRAF mutation was detected
in 40 of 60 PTC (66.7%) specimens. There was a statistical difference in BRAF mutations between
PTC and papillary benign lesions (P < 0.05); there were no associations between BRAF mutation and the
clinicopathological features of PTC.
Conclusion: Combined immunohistochemical staining of HBME-1, Galectin-3, and CK19 can further improve
the sensitivity and specificity of differential diagnosis of PTC. BRAF mutation is a significant genetic
event, which may have diagnostic value for PTC. |
| Close |
|
|
|